Search

Your search keyword '"Trypanosomiasis, African prevention & control"' showing total 651 results

Search Constraints

Start Over You searched for: Descriptor "Trypanosomiasis, African prevention & control" Remove constraint Descriptor: "Trypanosomiasis, African prevention & control"
651 results on '"Trypanosomiasis, African prevention & control"'

Search Results

1. Patterns of microbiome composition in tsetse fly Glossina palpalis palpalis during vector control using Tiny Targets in Campo, South Cameroon.

2. Impact of a national tsetse control programme to eliminate Gambian sleeping sickness in Uganda: a spatiotemporal modelling study.

3. Advancement in the development of DNA vaccines against Trypanosoma brucei and future perspective.

4. Modelling timelines to elimination of sleeping sickness in the Democratic Republic of Congo, accounting for possible cryptic human and animal transmission.

5. What is needed to achieve effective and sustainable control of African animal trypanosomosis?

6. Evaluation of the International Task Force for Disease Eradication: A Review of Past Deliberations.

7. Prophylactic activity of orally administered dry-heat-sterilized Acremonium egyptiacum against Trypanosoma congolense-induced animal African trypanosomosis.

8. Elimination of human African trypanosomiasis: The long last mile.

9. The Hidden Hand of Asymptomatic Infection Hinders Control of Neglected Tropical Diseases: A Modeling Analysis.

10. Modelled impact of Tiny Targets on the distribution and abundance of riverine tsetse.

11. The elimination of human African trypanosomiasis: Monitoring progress towards the 2021-2030 WHO road map targets.

12. Animal trypanosomosis eliminated in a major livestock production region in Senegal following the eradication of a tsetse population.

13. Limited impact of vector control on the population genetic structure of Glossina fuscipes fuscipes from the sleeping sickness focus of Maro, Chad.

14. Impact of a small-scale tsetse fly control operation with deltamethrin impregnated "Tiny Targets" on tsetse density and trypanosomes' circulation in the Campo sleeping sickness focus of South Cameroon.

15. Recent advances in genome editing of bloodstream forms of Trypanosoma congolense using CRISPR-Cas9 ribonucleoproteins: Proof of concept.

17. Towards the sustainable elimination of gambiense human African trypanosomiasis in Côte d'Ivoire using an integrated approach.

18. Health economic evaluation of strategies to eliminate gambiense human African trypanosomiasis in the Mandoul disease focus of Chad.

19. Evidence-based advice on timing and location of tsetse control measures in Shimba Hills National reserve, Kenya.

20. A modelling assessment of short- and medium-term risks of programme interruptions for gambiense human African trypanosomiasis in the DRC.

21. Vector competence of sterile male Glossina fuscipes fuscipes for Trypanosoma brucei brucei: implications for the implementation of the sterile insect technique in a sleeping sickness focus in Chad.

22. The national atlas of tsetse flies and African animal trypanosomosis in Ethiopia.

23. Health work and skills in the last mile of disease elimination. Experiences from sleeping sickness health workers in South Sudan and DR Congo.

24. Gambiense human African trypanosomiasis: the bumpy road to elimination.

25. Environmental mutations in the Campo focus challenge elimination of sleeping sickness transmission in Cameroon.

26. Modelling to infer the role of animals in gambiense human African trypanosomiasis transmission and elimination in the DRC.

27. Scaling up of tsetse control to eliminate Gambian sleeping sickness in northern Uganda.

28. Steroidal Antimetabolites Protect Mice against Trypanosoma brucei .

29. Clinical trials as disease control? The political economy of sleeping sickness in the Democratic Republic of the Congo (1996-2016).

30. Identifying regions for enhanced control of gambiense sleeping sickness in the Democratic Republic of Congo.

31. Review of the Situation of Human African Trypanosomiasis in the Republic of Congo From the 1950s to 2020.

32. An atlas to support the progressive control of tsetse-transmitted animal trypanosomosis in Burkina Faso.

33. Prevalence of Trypanosoma and Sodalis in wild populations of tsetse flies and their impact on sterile insect technique programmes for tsetse eradication.

34. Cost-effectiveness of sleeping sickness elimination campaigns in five settings of the Democratic Republic of Congo.

35. Update of transmission modelling and projections of gambiense human African trypanosomiasis in the Mandoul focus, Chad.

36. The elimination of human African trypanosomiasis: Achievements in relation to WHO road map targets for 2020.

37. The cost of tsetse control using 'Tiny Targets' in the sleeping sickness endemic forest area of Bonon in Côte d'Ivoire: Implications for comparing costs across different settings.

38. Monitoring the elimination of gambiense human African trypanosomiasis in the historical focus of Batié, South-West Burkina Faso.

39. 'Where are the dead flies!': perceptions of local communities towards the deployment of Tiny Targets to control tsetse in the Democratic Republic of the Congo.

40. Satellite-based modelling of potential tsetse (Glossina pallidipes) breeding and foraging sites using teneral and non-teneral fly occurrence data.

41. Modelling to explore the potential impact of asymptomatic human infections on transmission and dynamics of African sleeping sickness.

42. Pharma to farmer: field challenges of optimizing trypanocide use in African animal trypanosomiasis.

43. High-throughput hit-squad tackles trypanosomes.

44. Estimating the impact of Tiny Targets in reducing the incidence of Gambian sleeping sickness in the North-west Uganda focus.

45. Farmer perceptions and willingness to pay for novel livestock pest control technologies: A case of tsetse repellent collar in Kwale County in Kenya.

46. The potential economic benefits of controlling trypanosomiasis using waterbuck repellent blend in sub-Saharan Africa.

47. An invariant Trypanosoma vivax vaccine antigen induces protective immunity.

48. Use of vector control to protect people from sleeping sickness in the focus of Bonon (Côte d'Ivoire).

49. Feasibility of a dried blood spot strategy for serological screening and surveillance to monitor elimination of Human African Trypanosomiasis in the Democratic Republic of the Congo.

50. Cost-effectiveness modelling to optimise active screening strategy for gambiense human African trypanosomiasis in endemic areas of the Democratic Republic of Congo.

Catalog

Books, media, physical & digital resources